Obsidian® ASG

anastomoses safeguard

Obsidian® ASG

Obsidian® ASG – Anastomoses SafeGuard, a breakthrough in regenerative surgery serves as an anastomotic reinforcement, supplementing standard closing techniques after resection surgery in the gastrointestinal tract. It not only effectively seals and heals anastomoses, but also harnesses the body’s own regenerative capabilities to promote fast and effective healing, improving the overall recovery process.

  • Application of Obsidian® ASG following colorectal resection is related to a low rate of anastomotic leakages – 2.3%
    (6/261 patients)1
  • Application of Obsidian® ASG in colorectal resection is safe for patients undergoing gastrointestinal resection and
    related to a low rate of postoperative complications1
Table showing low rate of anastomotic leaks with Obsidian® ASG
  • Efficient air and liquid tight anastomosis sealing1
  • Immediate polymerization and adhesion to tissue – even when applied on vertical, inverted or moist surfaces6
  • Obsidian® ASG is highly elastic and conformable to movement – high mechanical protection and anastomotic burst pressure immediately after application1,2
Table where Obsidian® ASG demonstrates more
than double anastomotic burst pressure vs control
  • Acts as a source of angiogenic growth factors supporting tissue proliferation and growth of new blood vessels1,2
  • Can be used for staple line bleeding

Images showing Obsidian® ASG improves tissue healing

benefits of obsidian® asg

Resection surgery in the gastrointestinal tract is a common treatment of colorectal cancer, inflammatory bowel diseases and esophageal cancer. The most dreaded and devastating surgical complication following resection surgery is anastomotic leak, as this leads to increased morbidity, mortality, days in hospital and costs as well as impaired patient QoL.1,7
Current rates of anastomotic leaks following resection vary depending on anatomic site:
  • Colon: 4%8
  • Rectum: 10%8
  • Esophagus: 10%9

  • Patients experiencing an anastomotic leak have increased risk of significant morbidity10
  • Patients experiencing anastomotic leak have increased risk of mortality – 30-day mortality rate for patients experiencing an anastomotic leak is 10.6% versus 1.6% for patients with no an intact anastomosis11

obsidian® asg – easy to apply

  • Obsidian® ASG is easy to apply accurately
  • Compatible application devices and different spray modes offer a solution for various types of surgery (open surgery, endoscopy, laparoscopy, robotics)
  • The intra- and extra-anastomotic application technique sustains the sealing and healing of anastomoses

obsidian® ASG serves as a multi-level anastomoses safeguard

Intra-anastomotically applied Obsidian® ASG from Vivostat®

The photo shows the intra-anastomotically applied Obsidian® ASG providing bioactive sealing and enhancing anastomotic tissue healing.

Obsidian® ASG from Vivostat® covers the tatanium clamps

This photo is taken through a microscope and shows how Obsidian® ASG covers the titanium clamps and acts as a staple line reinforcement.

Anastomotic tissue healing on day 30 after Obsidian® ASG from Vivostat® was applied

The arrows point to the anastomotic site and show the anastomotic tissue healing on day 30 in a porcine study2

Play Video

Properties of obsidian®

Click on the video and see the amazing showcase of the application of Obsidian® ASG following deep anterior rectum resection. 

obsidian® ASG is designed to be a cost-effective solution for anastomotic procedures1

  • Anastomotic leak increases length of stay in hospital12
  • Costs associated with a patient experiencing anastomotic leak are up to 4 times higher than those incurred by a patient with no surgical complications12
Table showing anastomotic leak incurs high costs in colorectal surgery

Improve patient safety

Reduce reoperations

Reduce days in hospital

Product order codes obsidian® ASG

Application devices

The Vivostat® System offers a variety of different disposable application devic­es as well as a number of reusable handles.

General surgery

The ability to use the Vivostat® Endoscopic Applicator in general surgery has proven very useful.

  1. Shamiyeh, A., Klugsberger, B., Aigner, C., Schimetta, W., Herbst, F., & Dauser, B. (2021), Obsidian ASG autologous platelet-rich fibrin matrix and colorectal anastomotic healing – a preliminary study, Surgical Technology International, 39, 147-154, https://doi.org/10.52198/21.sti.39.cr11508
  2. Dauser, B., Heitland, W., Bader, F. G., Brunner, W., Nir, Y., & Zbar, A. P.  (2019), Histologic changes in early colonic anastomotic healing using autologous platelet-rich fibrinmatrix, European Surgery, 52(4), 155-164, https://doi.org/10.1007/s10353-019-0578-9
  3. Bayer, A., Lammel, J., Rademacher, F., Groß, J., Siggelkow, M., Lippross, S., Klüter, T., Varoga, D., Tohidnezhad, M., Pufe, T., Cremer, J., Gläser, R., & Harder, J. (2016), Platelet-released growth factors induce the antimicrobial peptide human beta-defensin- 2 in primary keratinocytes, Experimental Dermatology, 25(6), 460–465, https://doi.org/10.1111/exd.12966
  4. Knafl, D., Thalhammer, F., & Vossen, M. G.  (2017), In-vitro release pharmacokinetics of amikacin teicoplanin and polyhexanide in a platelet rich fibrin layer (PRF) a laboratory evaluation of a modern, autologous wound treatment, PLoS One e, 12(7), e0181090, https://doi.org/10.1371/journal.pone.0181090
  5. Tohidnezhad, M., Varoga, D., Podschun, R., Wruck, C. J., Seekamp, A., Brandenburg, L., Pufe, T., & Lippross, S. (2011). Thrombocytes are effectors of the innate immune system releasing human beta defensin-3. Injury-International Journal of the Care of the Injured, 42(7), 682–686. https://doi.org/10.1016/j.injury.2010.12.010
  6. Kjaergard, H. K., Velada, J. L., Pedersen, J. H., Fleron, H., & Hollingsbee, D. (2000), Comparative kinetics of polymerisation of three fibrin sealant and influence on thiming of tissue adhesion, Thrombosis Research , 98(2), 221–228, https://doi.org/10.1016/s0049-3848(99)00234-0
  7. Sciuto, A., Merola, G., De Palma, G. D., Sodo, M., Pirozzi, F., Bracale, U., & Bracale, U. (2018). Predictive factors for anastomotic leakage after laparoscopic colorectal surgery. World Journal of Gastroenterology, 24(21), 2247–2260. https://doi.org/10.3748/wjg.v24.i21.2247
  8. DCCG. (2023, October 3). Danish Colorectal Cancer Group Annual Report 2021. https://dccg.dk/arsrapporter/
  9. RKKP. (2023, November 28). Danish EsophagoGastric Cancer Group database – Annual report 2021 RKKP’S Knowledge Center https://www.rkkp.dk/
  10. Turrentine, F. E., Denlinger, C. E., Simpson, V. B., Garwood, R. A., Guerlain, S., Agrawal, A., Friel, C. M., LaPar, D. J., Stukenborg, G. J., & Jones, R. S. (2015). Morbidity, mortality, cost, and survival estimates of gastrointestinal anastomotic leaks. Journal of the American College of Surgeons, 220(2), 195–206. https://doi.org/10.1016/j.jamcollsurg.2014.11.002
  11. Frasson, M., Battersby, N., Bhangu, A., Hervás, D., El‐Hussuna, A., Gallo, G., Pata, F., Pinkney, T., Poškus, T., Singh, B., Investigators, L., Bernstein, I., Sunesen, K. G., Leunbach, J., Thorlacius-Ussing, O., & Ovesen, A. U. (2020). Predictors for anastomotic leak, postoperative complications, and mortality after right colectomy for cancer: results from an international snapshot audit. Diseases of the Colon & Rectum, 63(5), 606–618. https://doi.org/10.1097/dcr.0000000000001590
  12. La Regina, D., Di Giuseppe, M., Lucchelli, M., Saporito, A., Boni, L., Efthymiou, C. A., Cafarotti, S., Marengo, M., & Mongelli, F. (2018). Financial impact of anastomotic leakage in colorectal surgery. Journal of Gastrointestinal Surgery, 23(3), 580–586. https://doi.org/10.1007/s11605-018-3954-z
  13. Enodien, B., Maurer, A., Ochs, V., Bachmann, M. F., Gripp, M., Frey, D. M., & Taha, A. (2022). The Effects of Anastomotic Leaks on the Net Revenue from Colon Surgery. International Journal of Environmental Research and Public Health, 19(15), 9426. https://doi.org/10.3390/ijerph19159426
  14. ClinicalTrials.gov. (n.d.). https://clinicaltrials.gov/ct2/show/NCT05174910